Cumbo Alexander 4
4 · Solid Biosciences Inc. · Filed Apr 21, 2026
Research Summary
AI-generated summary of this filing
Solid Biosciences CEO Alexander Cumbo Receives 169,401 RSUs
What Happened
Alexander Cumbo, President, CEO and a Director of Solid Biosciences (SLDB), was granted/acquired 169,401 restricted stock units (RSUs) on January 29, 2026. The transaction is reported as a derivative award with a reported acquisition price of $0.00 (no cash exchanged on grant).
Key Details
- Transaction date: 2026-01-29; Form 4 filed: 2026-04-21 (filing appears late relative to the 2-business-day Form 4 deadline).
- Award: 169,401 RSUs (reported as a derivative "A" award); transaction value recorded as $0.00.
- Footnote F1: Each RSU represents a contingent right to receive one share of common stock.
- Footnote F2: These relate to performance stock units (PSUs) originally granted June 11, 2024; 25% of target PSUs vest upon each of four independent non-market, non-financial performance milestones. The Board certified the second milestone was met on Jan 29, 2026. Shares tied to that milestone will vest only if the grantee remains in service on the Evaluation Date (anticipated in Q1 2027).
- Shares owned after the transaction: not specified in the provided filing.
Context
This is a performance-based equity award (derivative RSUs/PSUs), not an open-market purchase or sale. No cash changed hands at grant; vesting is contingent on future service and achievement certification previously made by the Board. The late filing may be material to timing disclosure — check the full SEC filing for any explanations or amendments.
Insider Transaction Report
- Award
Restricted Stock Units
[F1][F2]2026-01-29+169,401→ 169,401 total→ Common Stock (169,401 underlying)
Footnotes (2)
- [F1]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").
- [F2]Performance stock units ("PSUs") were granted on June 11, 2024, and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the second Performance Milestone was determined by the Board to be met on January 29, 2026, and the shares related to such Performance Milestone will vest subject to the grantee's continued service with the Company on the Evaluation Date, which is anticipated to occur in the first quarter of 2027.